Abstract: User biometric information based authentication techniques are provided for a wearer of a near-eye display device in engagement with multimedia content and/or access to restricted data. Biological and/or behavioral biometric information associated with the user may be captured through sensors and similar devices integrated or communicatively coupled to the near-eye display device. The biological biometric information may include data associated with a user's face, fingerprint, palmprint, iris, retina, cardio-electrical signals, etc. The behavioral biometric information may include data associated with a user's movement, gait, gesture(s), voice, etc. An authentication technique may be automatically select one based on environmental conditions (e.g., noise or light levels). Near-eye display device may detect continuous wearing by the user and refresh or continue authentication following a period of non-use or between two different authenticated sessions.

Abstract: Example smart glasses comprise one or more lenses and a LED on a portion of the smart glasses, the portion of the smart glasses facing towards an eye of a user such that a light emitted from the LED is visible i) to the eye of the user and ii) from the portion of the smart glasses not including the one or more lenses. The smart glasses are configured to receive an indication corresponding to a first message for the user, and responsive to receiving the indication corresponding to the first message for the user, present, via the LED, a first light-based representation of the first message. The smart glasses are configured to receive an indication corresponding to a second message for the user, and responsive to receiving the indication corresponding to the second message for the user, present, via the LED, a second light-based representation of the second message.

Abstract: Systems and methods for detecting tampering with bystander privacy indicators are disclosed. A method performed at a head-wearable device worn by a user includes detecting, via an ambient light sensor of a head-wearable device, a first amount of light in an environment, and detect, via the imaging device of the head-wearable device, a second amount of light in the environment. The method further includes, responsive to user input for capturing image data via the imaging device of the head-wearable device, determining a brightness ratio. The brightness ratio is based on a relationship between the first amount of light and the second amount of light in the environment. The method includes, in accordance with a determination that the brightness ratio satisfies a tamper threshold, capturing image data; and, in accordance with a determination that the brightness ratio does not satisfy the tamper threshold, forgoing capturing image data.

Abstract: User biometric information based authentication techniques are provided for a wearer of a near-eye display device in engagement with multimedia content and/or access to restricted data. Biological and/or behavioral biometric information associated with the user may be captured through sensors and similar devices integrated or communicatively coupled to the near-eye display device. The biological biometric information may include data associated with a user's face, fingerprint, palmprint, iris, retina, cardio-electrical signals, etc. The behavioral biometric information may include data associated with a user's movement, gait, gesture(s), voice, etc. An authentication technique may be automatically select one based on environmental conditions (e.g., noise or light levels). Near-eye display device may detect continuous wearing by the user and refresh or continue authentication following a period of non-use or between two different authenticated sessions.

Abstract: In one embodiment a device for tightening and loosening a securing device is provided. The device includes a housing, a shaft, and a clutch assembly. In one embodiment, the clutch assembly includes a clutch activation member, a first friction member coupled to the clutch activation member, and a second friction member coupled to the shaft. When the clutch activation member is in a first position, the clutch activation member engages the first friction member with the second friction member for transmission of torque from the first friction member to the second friction member. When the clutch activation member is in the second position, the clutch activation member disengages the first friction member from the second friction member to prevent transmission of the torque from the first friction member to the second friction member.

Abstract: In one embodiment a device for tightening and loosening a securing device is provided. The device includes a housing, a shaft, and a clutch assembly. In one embodiment, the clutch assembly includes a clutch activation member, a first friction member coupled to the clutch activation member, and a second friction member coupled to the shaft. When the clutch activation member is in a first position, the clutch activation member engages the first friction member with the second friction member for transmission of torque from the first friction member to the second friction member. When the clutch activation member is in the second position, the clutch activation member disengages the first friction member from the second friction member to prevent transmission of the torque from the first friction member to the second friction member.

Abstract: Some of the embodiments of the present disclosure provide an integrated circuit (IC) chip comprising a die, a system on chip (SOC) coupled to the die, and an internal test engine included in the SOC and configured to test the die, wherein one or more components within the IC chip may be configured to be tested by an external test engine coupled to the IC chip. Other embodiments are also described and claimed.

Abstract: Some of the embodiments of the present disclosure provide an integrated circuit (IC) chip comprising a die, a system on chip (SOC) coupled to the die, and an internal test engine included in the SOC and configured to test the die, wherein one or more components within the IC chip may be configured to be tested by an external test engine coupled to the IC chip. Other embodiments are also described and claimed.

Abstract: A method for improving the solar energy condensation efficiency in the solar energy condensation electric power facility is provided. A corresponding twice condensing prism (11) is provided under a condensing lens. A corresponding solar cell is provided under the twice condensing prism. Reflective mirrors (21) are provided around the twice condensing prism. The twice condensing prism is provided in the reflective mirrors. The central axis of the twice condensing prism and the reflective mirrors are coincided. The distance between the normal line of the plane of the light incidence of the twice condensing prism and the reflective mirrors is greater than the distance between the normal line of the plane of the light emergence of the twice condensing prism and the reflective mirrors. The method can uniform the solar energy condensation, and improve the tolerance of the twice optical system.

Abstract: Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Abstract: Methods for diagnosing and treating prostate cancer are disclosed. In practicing the method, a subject's body-fluid sample is assayed for GPC3 protein, and the GPC3 level observed is used in determining whether the subject has an elevated GPC3 level associated with prostate cancer. Patients with such elevated levels may be treated, in accordance with the invention, with a variety of GPC3-related immunotherapy agents.

Abstract: Devices and methods for diagnosing and treating prostate cancer are disclosed. In practicing the method, a subject's body-fluid sample is assayed for GPC3 protein, and the GPC3 level observed is used in determining whether the subject has an elevated GPC3 level associated with prostate cancer. Patients with such elevated levels may be treated, in accordance with the present disclosure, with a variety of GPC3-related immunotherapy agents.

Abstract: Methods, reagents and kits for diagnosing and treating cancer such as kidney or colorectal cancer are disclosed. An immunoassay for detecting kidney or colorectal cancer is based on the relative change of the ADAMTSL4 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney or colorectal cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Abstract: Provided is an immunotoxin including (a) an anti-CD19 antibody lacking an Fc fragment, (b) a modified exotoxin A protein having both Domains II and III, but lacking Domain I, and (c) a peptide linker joining the C-terminal end of the antibody to the N-terminal end of the modified exotoxin A protein. The linker is substantially resistant to extracellular cleavage. The modified exotoxin A protein may be further modified to include a C-terminal KDEL sequence (SEQ ID NO: 6) that promotes transport of the protein to the endoplasmic reticulum of cells that have taken up the immunotoxin. Also provided is an anti-CD19 antibody having enhanced binding activity, antibody-dependent cellular cytotoxicity (ADCC) and methods for using the antibody to treat a disease state associated with B-lineage cells that express CD19. The antibody variable light and variable heavy chains have unique sequences in their J region relative to known anti-CD19 antibody sequences.

Abstract: Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Abstract: Methods, reagents and kits for diagnosing and treating cancer such as kidney or colorectal cancer are disclosed. An immunoassay for detecting kidney or colorectal cancer is based on the relative change of the ADAMTSL4 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney or colorectal cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Abstract: Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Abstract: A method of identifying regulatory RNAs, including miRNAs, using insertional mutagenesis to generate tumors in mice and determining the human orthologs is disclosed. Further, specific miRNA sequences are identified. The causal nature and expression patterns of these regulatory RNAs and miRNAs in human tumors demonstrate their utility in diagnosis and therapy of cancer. Furthermore, a set of co-mutations that act in conjunction with miRNAs in tumor formation is disclosed.

Abstract: Methods, reagents and kits for diagnosing and treating cancer such as kidney or colorectal cancer are disclosed. An immunoassay for detecting kidney or colorectal cancer is based on the relative change of the ADAMTSL4 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney or colorectal cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Abstract: Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.